These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Stem cells in age-related macular degeneration and Stargardt's macular dystrophy. Zhang GY; Liao T; Fu XB; Li QF Lancet; 2015 Jul; 386(9988):29-30. PubMed ID: 26169863 [No Abstract] [Full Text] [Related]
29. Wnt/β-Catenin Signaling Mediates Regeneration of Retinal Pigment Epithelium After Laser Photocoagulation in Mouse Eye. Han JW; Lyu J; Park YJ; Jang SY; Park TK Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):8314-24. PubMed ID: 26720485 [TBL] [Abstract][Full Text] [Related]
30. Human embryonic stem cells. Damdimopoulou P; Rodin S; Stenfelt S; Antonsson L; Tryggvason K; Hovatta O Best Pract Res Clin Obstet Gynaecol; 2016 Feb; 31():2-12. PubMed ID: 26602389 [TBL] [Abstract][Full Text] [Related]
31. Trials of embryonic stem cells to launch in China. Cyranoski D Nature; 2017 May; 546(7656):15-16. PubMed ID: 28569831 [No Abstract] [Full Text] [Related]
33. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. Lu B; Malcuit C; Wang S; Girman S; Francis P; Lemieux L; Lanza R; Lund R Stem Cells; 2009 Sep; 27(9):2126-35. PubMed ID: 19521979 [TBL] [Abstract][Full Text] [Related]
34. Expanded polytetrafluoroethylene as a substrate for retinal pigment epithelial cell growth and transplantation in age-related macular degeneration. Krishna Y; Sheridan C; Kent D; Kearns V; Grierson I; Williams R Br J Ophthalmol; 2011 Apr; 95(4):569-73. PubMed ID: 21317216 [TBL] [Abstract][Full Text] [Related]
35. [New understanding and development of medical treatments for ocular diseases based upon molecular mechanisms]. Tanihara H Nippon Ganka Gakkai Zasshi; 2005 Dec; 109(12):917-59; discussion 960-1. PubMed ID: 16408490 [TBL] [Abstract][Full Text] [Related]
36. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy]. Tamaki Y Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564 [TBL] [Abstract][Full Text] [Related]
37. Perspectives on human clinical trials of therapies using iPS cells in Japan: reaching the forefront of stem-cell therapies. Song P; Inagaki Y; Sugawara Y; Kokudo N Biosci Trends; 2013 Jun; 7(3):157-8. PubMed ID: 23836040 [TBL] [Abstract][Full Text] [Related]
38. Cell therapy for macular degeneration--first phase I/II pluripotent stem cell-based clinical trial shows promise. Chen Z; Zhang YA Sci China Life Sci; 2015 Jan; 58(1):119-20. PubMed ID: 25528254 [No Abstract] [Full Text] [Related]
39. Current status of pluripotent stem cells: moving the first therapies to the clinic. Kimbrel EA; Lanza R Nat Rev Drug Discov; 2015 Oct; 14(10):681-92. PubMed ID: 26391880 [TBL] [Abstract][Full Text] [Related]
40. Cataract surgery and macular degeneration progression. Seigel D Ophthalmology; 2009 Dec; 116(12):2482-3; author reply 2483. PubMed ID: 19948287 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]